1. ZhongP, AgostoLM, MunroJB, MothesW (2013) Cell-to-cell transmission of viruses. Curr Opin Virol 3: 44–50.
2. SattentauQ (2008) Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 6: 815–826.
3. MeredithLW, HarrisHJ, WilsonGK, FletcherNF, BalfeP, et al. (2013) Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. J Hepatol 58: 1074–1080.
4. TimpeJM, StamatakiZ, JenningsA, HuK, FarquharMJ, et al. (2008) Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47: 17–24.
5. ZeiselMB, LupbergerJ, FofanaI, BaumertTF (2013) Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol 58: 375–384.
6. LupbergerJ, ZeiselMB, XiaoF, ThumannC, FofanaI, et al. (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17: 589–595.
7. ZonaL, LupbergerJ, Sidahmed-AdrarN, ThumannC, HarrisHJ, et al. (2013) HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 13: 302–313.
8. ZahidMN, TurekM, XiaoF, Dao ThiVL, GuerinM, et al. (2013) The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 57: 492–504.
9. FofanaI, XiaoF, ThumannC, TurekM, ZonaL, et al. (2013) A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One 8: e64221.
10. CataneseMT, LoureiroJ, JonesCT, DornerM, von HahnT, et al. (2013) Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol 87: 8282–8293.
11. WitteveldtJ, EvansMJ, BitzegeioJ, KoutsoudakisG, OwsiankaAM, et al. (2009) CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 90: 48–58.
12. BrimacombeCL, GroveJ, MeredithLW, HuK, SyderAJ, et al. (2011) Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 85: 596–605.
13. KwonH, LokAS (2011) Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 8: 275–284.
14. TronoD, Van LintC, RouziouxC, VerdinE, Barre-SinoussiF, et al. (2010) HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329: 174–180.
15. McHutchisonJG, MannsMP, MuirAJ, TerraultNA, JacobsonIM, et al. (2010) Telaprevir for previously treated chronic HCV infection. N Engl J Med 362: 1292–1303.
16. PoordadF, McConeJJr, BaconBR, BrunoS, MannsMP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195–1206.
17. RongL, DahariH, RibeiroRM, PerelsonAS (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2: 30ra32.
18. LangeCM, ZeuzemS (2013) Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 58: 583–592.
19. PawlotskyJM (2013) Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 369: 321–342.
20. SarrazinC, HezodeC, ZeuzemS, PawlotskyJM (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56 Suppl 1S88–100.
21. LokAS, GardinerDF, LawitzE, MartorellC, EversonGT, et al. (2012) Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366: 216–224.
22. JacobsonIM, GordonSC, KowdleyKV, YoshidaEM, Rodriguez-TorresM, et al. (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867–1877.
23. GaneEJ, StedmanCA, HylandRH, DingX, SvarovskaiaE, et al. (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34–44.
24. PoordadF, LawitzE, KowdleyKV, CohenDE, PodsadeckiT, et al. (2013) Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 368: 45–53.
25. TremblingPM, TanwarS, RosenbergWM, DusheikoGM (2013) Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol 10: 713–728.
26. LiangTJ, GhanyMG (2013) Current and future therapies for hepatitis C virus infection. N Engl J Med 368: 1907–1917.
27. SorianoV, VispoE, PovedaE, LabargaP, BarreiroP (2012) Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 13: 313–323.
28. GottweinJM, JensenSB, LiYP, GhanemL, ScheelTK, et al. (2013) Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. Antimicrob Agents Chemother 57: 1291–1303.
29. HezodeC, FontaineH, DorivalC, LarreyD, ZoulimF, et al. (2013) Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 59: 434–441.
30. ZhongJ, GastaminzaP, ChengG, KapadiaS, KatoT, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102: 9294–9299.
31. JonesCT, CataneseMT, LawLM, KhetaniSR, SyderAJ, et al. (2010) Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol 28: 167–171.
32. Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, et al.. (2010) Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139: : 953–964, 964 e951–954.
33. OwsiankaA, TarrAW, JuttlaVS, LavilletteD, BartoschB, et al. (2005) Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79: 11095–11104.
34. Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, et al.. (2012) Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 143: : 223–233 e229.
35. KeckZY, XiaJ, WangY, WangW, KreyT, et al. (2012) Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog 8: e1002653.
36. KoutsoudakisG, KaulA, SteinmannE, KallisS, LohmannV, et al. (2006) Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 80: 5308–5320.
37. PietschmannT, KaulA, KoutsoudakisG, ShavinskayaA, KallisS, et al. (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 103: 7408–7413.
38. WakitaT, PietschmannT, KatoT, DateT, MiyamotoM, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791–796.
39. ZhuH, Wong-StaalF, LeeH, SyderA, McKelvyJ, et al. (2012) Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis 205: 656–662.
40. ScheelTK, GottweinJM, MikkelsenLS, JensenTB, BukhJ (2011) Recombinant HCV variants with NS5A from genotypes 1–7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 140: 1032–1042.
41. ZeiselMB, KoutsoudakisG, SchnoberEK, HaberstrohA, BlumHE, et al. (2007) Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46: 1722–1731.
42. KuonenF, TouvreyC, LaurentJ, RueggC (2010) Fc block treatment, dead cells exclusion, and cell aggregates discrimination concur to prevent phenotypical artifacts in the analysis of subpopulations of tumor-infiltrating CD11b(+) myelomonocytic cells. Cytometry A 77: 1082–1090.
43. SainzBJr, ChisariFV (2006) Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol 80: 10253–10257.
44. PietschmannT, ZayasM, MeulemanP, LongG, AppelN, et al. (2009) Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog 5: e1000475.
45. PawlotskyJM (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53: 1742–1751.
46. GottweinJM, ScheelTK, JensenTB, LademannJB, PrentoeJC, et al. (2009) Development and characterization of hepatitis C virus genotype 1–7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49: 364–377.
47. Bauhofer O, Ruggieri A, Schmid B, Schirmacher P, Bartenschlager R (2012) Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. Gastroenterology 143: : 429–438 e428.
48. LenzO, VerbinnenT, LinTI, VijgenL, CummingsMD, et al. (2010) In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54: 1878–1887.
49. BartoliniB, GiombiniE, ZaccaroP, SelleriM, RozeraG, et al. (2013) Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients. Virus Res 177: 205–208.
50. GroveJ, NielsenS, ZhongJ, BassendineMF, DrummerHE, et al. (2008) Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 82: 12020–12029.
51. PawlotskyJM (2013) NS5A inhibitors in the treatment of hepatitis C. J Hepatol 59: 375–382.
52. LeeC, MaH, HangJQ, LevequeV, SklanEH, et al. (2011) The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 414: 10–18.
53. SigalA, KimJT, BalazsAB, DekelE, MayoA, et al. (2011) Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477: 95–98.
54. AbelaIA, BerlingerL, SchanzM, ReynellL, GunthardHF, et al. (2012) Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog 8: e1002634.
55. YanH, ZhongG, XuG, HeW, JingZ, et al. (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1: e00049.
56. HaidS, GretheC, DillMT, HeimM, KaderaliL, et al. (2014) Isolate-dependent use of Claudins for cell entry by hepatitis C virus. Hepatology 59: 24–34.
57. FofanaI, ZonaL, ThumannC, HeydmannL, DurandSC, et al. (2013) Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. J Virol 87: 10405–10410.
58. MassonD, KosekiM, IshibashiM, LarsonCJ, MillerSG, et al. (2009) Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol 29: 2054–2060.
59. CataldoVD, GibbonsDL, Perez-SolerR, Quintas-CardamaA (2011) Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 364: 947–955.
60. ShiN, HiragaN, ImamuraM, HayesCN, ZhangY, et al. (2013) Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut 62: 1055–1061.
61. SulkowskiMS, KangM, MatiningR, WylesD, JohnsonVA, et al. (2014) Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis 209: 658–667.
62. TarrAW, LafayeP, MeredithL, Damier-PiolleL, UrbanowiczRA, et al. (2013) An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 58: 932–939.
63. NathanC (2012) Fresh approaches to anti-infective therapies. Sci Transl Med 4: 140sr142.
64. FofanaI, JilgN, ChungRT, BaumertTF (2014) Entry inhibitors and future treatment of hepatitis C. Antiviral Res 104: 136–142.